Loncastuximab (ZYNLONTA) – Mechanism of Action
Loncastuximab (ZYNLONTA) – Hypersensitivity Incidence & Management
Loncastuximab (ZYNLONTA) – Dosing and Administration
Loncastuximab (ZYNLONTA) – Adjusted Body Weight Formula and Rationale
Loncastuximab (ZYNLONTA) – Cutaneous Reactions Management Flashcard
Loncastuximab (ZYNLONTA) – Myelosuppression Incidence and Management
Loncastuximab (ZYNLONTA)- Effusion, Edema incidence and management
Loncastuximab (ZYNLONTA) – Liver Enzyme Elevation Incidence and Management
ADCT Medical Podcast – Bridges Episode 3 (Managing Novel DLBCL Therapies in the Community)
Integrating novel therapies like bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) into community oncology practices can be a complex process. On this episode of Bridges, Dr. Lunning and Dr. Graff speak with Dr. Iqra Choudary about how she integrated BsAbs and ADCs into her practice with a proactive multidisciplinary team, strong safety protocols, comprehensive staff training, and strategic hospital partnerships.
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Iqra Choudary, board certified in Internal Medicine, Hematology-Oncology Associates of Central New York